Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease

Yoon, Jee-Eun; Kim, Ji Sun; Jang, Wooyoung; Park, Jinse; Oh, Eungseok; Youn, Jinyoung; Park, Suyeon; Cho, Jin Whan

doi:10.1159/000479111

Cited by 27 publications

(32 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 5950 studies were identified in target databases and 2 other studies were retrieved from reference lists. The final sample included in the meta‐analysis consisted of 20 studies with 2707 PD patients and 150,661 healthy controls 8,9,13,27‐41 …”

Section: Resultsmentioning

confidence: 99%

“…Four studies applied PDQ‐39 13,30,41,55 and all of them had available data and were included in the meta‐analysis. Other QOL measures were also used such as the generic 15D questionnaire (15D), 56 the Health Utilities Index Mark 3 (HUI3), 57 Nottingham Health Profile (NHP), 58,59 the Life Satisfaction Questionnaire (LiSat‐11), 60 an item of the International Prostate Symptom Score (IPSS) 61 and a newly developed QOL questionnaire 36 …”

Section: Resultsmentioning

confidence: 99%

“…Eventually, 20 studies with available data in both patient and control groups 8,9,12,13,27‐35,37‐41,49,52 were included in the meta‐analysis.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

et al. 2020

View full text Add to dashboard Cite

Background Studies regarding the impact of Parkinson's disease (PD) on quality of life (QOL) have reported conflicting results, and the underlying QOL domains require further study. In order to understand the association between PD and QOL, we conducted this meta‐analysis to systematically compare QOL between PD patients and healthy controls. Method The PubMed, PsycINFO, EMBASE, and Web of Science databases were systematically searched. Data were analyzed using the random‐effects model. Results Twenty studies covering 2707 PD patients and 150,661 healthy controls were included in the study. Compared with healthy controls, PD patients had significantly poorer QOL overall and in most domains with moderate to large effects sizes. Different QOL measures varied in their association with quality of life, with the Parkinson's Disease Questionnaire‐39 (PDQ‐39) having the largest effect size (standard mean difference, SMD = −1.384, 95% CI: −1.607, −1.162, Z = 12.189, P < 0.001), followed by the Europe Quality of Life Questionnaire‐visual analogue scale (EQ‐VAS) (SMD = −1.081, 95% CI: −1.578, −0.584, Z = −4.265, P < 0.001), Europe Quality of Life Questionnaire‐5D (EQ‐5D) (SMD = −0.889, 95% CI: −1.181, −0.596, Z = −5.962, P < 0.001), and the Short‐form Health Survey (SF) scales (physical dimension: SMD = −0.826, 95% CI: −1.529, −0.123, Z = −2.303, P = 0.021; mental dimension: SMD = −0.376, 95% CI: −0.732, −0.019, Z = −2.064, P = 0.039). Conclusion PD patients had lower QOL compared with healthy controls in most domains, especially in physical function and mental health. Considering the negative impact of poor QOL on daily life and functional outcomes, effective measures should be developed to improve QOL in this population.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, female PD patients showed lower QOL than male patients. The sex differences in nonmotor symptoms have been widely investigated [18], and it has been considered that socioeconomic status, occupational functioning, and hormonal differences between the sexes could contribute to these differences. This finding is in line with current published evidence that practitioners should be concerned with managing nonmotor symptoms as well as motor symptoms in de novo PD patients [19].…”

Section: Discussionmentioning

confidence: 99%

The Impact of Impulsivity on Quality of Life in Early Drug-Naïve Parkinson’s Disease Patients

Ryu

Kim²,

Yoo

et al. 2019

JMD

View full text Add to dashboard Cite

ObjectiveImpulse control disorders (ICDs) in Parkinson’s disease (PD) are mostly related to dopamine replacement therapy (DRT); however, drug-naïve PD patients have also frequently experienced impulsivity. This phenomenon makes clinicians hesitate treating patients with DRT. In this study, we assessed the effect of impulsivity on quality of life (QOL) in drug-naïve PD patients.MethodsTwo hundred three newly diagnosed, nonmedicated PD patients were enrolled, and they received structured clinical interviews, physical examinations and validated questionnaires to evaluate motor and nonmotor symptoms and QOL. Impulsivity was evaluated using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS).ResultsThirty-eight patients (18.7%) had impulsivity with QUIP-RS scores ≥ 1 and 4 patients (2.0%) were diagnosed with combined ICDs. Motor and nonmotor symptoms were significantly correlated with the Parkinson’s Disease Questionnaire-39 summary index. Female sex and QUIP-RS scores were also correlated with QOL in drug-naïve PD patients.ConclusionThe results of the present study showed that impulsivity negatively influences QOL in early drug-naïve PD patients. In addition, more severe motor and nonmotor symptoms were also associated with lower QOL. Such findings complicate treatment but provide valuable information for managing early PD.

show abstract

“…Over all, further studies on a large number of patients and long follow up are needed to determine the impact of DBS on QOL taking into account both motor and non-motor symptoms. The moderate improvement of QOL by STN DBS reported up to now highlights the major influence of nonmotor symptoms on quality of life ( 67 , 68 ).…”

Section: Discussionmentioning

confidence: 94%

Deep Brain Stimulation in Moroccan Patients With Parkinson's Disease: The Experience of Neurology Department of Rabat

et al. 2018

View full text Add to dashboard Cite

Introduction: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is known as a therapy of choice of advanced Parkinson's disease. The present study aimed to assess the beneficial and side effects of STN DBS in Moroccan Parkinsonian patients.Material and Methods: Thirty five patients underwent bilateral STN DBS from 2008 to 2016 in the Rabat University Hospital. Patients were assessed preoperatively and followed up for 6 to 12 months using the Unified Parkinson's Disease Rating Scale in four conditions (stimulation OFF and ON and medication OFF and ON), the levodopa-equivalent daily dose (LEDD), dyskinesia and fluctuation scores and PDQ39 scale for quality of life (QOL). Postoperative side effects were also recorded.Results: The mean age at disease onset was 42.31 ± 7.29 years [28–58] and the mean age at surgery was 54.66 ± 8.51 years [34–70]. The median disease duration was 11.95 ± 4.28 years [5–22]. Sixty-three percentage of patients were male. 11.4% of patients were tremor dominant while 45.71 showed akinetic-rigid form and 42.90 were classified as mixed phenotype. The LEDD before surgery was 1200 mg/day [800-1500]. All patients had motor fluctuations whereas non-motor fluctuations were present in 61.80% of cases. STN DBS decreased the LEDD by 51.72%, as the mean LEDD post-surgery was 450 [188-800]. The UPDRS-III was improved by 52.27%, dyskinesia score by 66.70% and motor fluctuations by 50%, whereas QOL improved by 27.12%. Post-operative side effects were hypophonia (2 cases), infection (3 cases), and pneumocephalus (2 cases).Conclusion: Our results showed that STN DBS is an effective treatment in Moroccan Parkinsonian patients leading to a major improvement of the most disabling symptoms (dyskinesia, motor fluctuation) and a better QOL.

show abstract

Gender Differences of Nonmotor Symptoms Affecting Quality of Life in Parkinson Disease

Cited by 27 publications

References 25 publications

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

Quality of life in Parkinson's disease: A systematic review and meta‐analysis of comparative studies

The Impact of Impulsivity on Quality of Life in Early Drug-Naïve Parkinson’s Disease Patients

Deep Brain Stimulation in Moroccan Patients With Parkinson's Disease: The Experience of Neurology Department of Rabat

Contact Info

Product

Resources

About